Cunningham D, Powles T J, Dowsett M, Hutchison G, Brodie A M, Ford H T, Gazet J C, Coombes R C
Medical Oncology Unit, St. George's Hospital, London, UK.
Cancer Chemother Pharmacol. 1987;20(3):253-5. doi: 10.1007/BF00570496.
Thirty-one post-menopausal female patients, with locally advanced or disseminated breast cancer were treated with the aromatase inhibitor 4-hydroxyandrostenedione given orally at a dose of 500 mg daily. Twenty-nine patients had assessable disease. Eight patients (28%) had objective evidence of partial response and six remain in remission 7-10 months later. A further four patients (14%) had stabilisation of disease and 11 patients (37%) had progressive disease in spite of treatment. Plasma oestradiol levels were measured throughout therapy in 16 patients and were lowered to 53% +/- 8% of baseline levels within 7 days of commencing 4-hydroxyandrostenedione. With regard to toxicity, one patient developed a transient skin rash and another patient some facial swelling. A further patient developed a transient leucopaenia and treatment was therefore discontinued. Twenty-seven of the 30 evaluable patients (90%) experienced no side effects. These results indicate that oral administration of 4-hydroxyandrostenedione is an acceptable new treatment for post-menopausal women with disseminated breast cancer.
31名绝经后女性局部晚期或转移性乳腺癌患者接受了芳香化酶抑制剂4-羟基雄烯二酮治疗，口服剂量为每日500毫克。29名患者具有可评估疾病。8名患者（28%）有部分缓解的客观证据，6名患者在7至10个月后仍处于缓解期。另有4名患者（14%）疾病稳定，11名患者（37%）尽管接受了治疗仍有疾病进展。在16名患者的整个治疗过程中测量了血浆雌二醇水平，在开始使用4-羟基雄烯二酮的7天内，血浆雌二醇水平降至基线水平的53%±8%。关于毒性，1名患者出现短暂皮疹，另1名患者出现面部肿胀。另有1名患者出现短暂性白细胞减少，因此停止治疗。30名可评估患者中的27名（90%）未出现副作用。这些结果表明，口服4-羟基雄烯二酮是绝经后转移性乳腺癌女性的一种可接受的新治疗方法。
